These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Use of an artificial antigen containing the 3,6-di-O-methyl-beta-D-glucopyranosyl epitope for the serodiagnosis of leprosy.
    Author: Cho SN, Fujiwara T, Hunter SW, Rea TH, Gelber RH, Brennan PJ.
    Journal: J Infect Dis; 1984 Sep; 150(3):311-22. PubMed ID: 6207246.
    Abstract:
    The coupling of synthetic 3,6-di-O-methyl-beta-D-glucopyranosyl-(1----4)-2,3-di-O-methyl-alpha-L -rhamnopyranose, the hapten determinant of phenolic glycolipid I from Mycobacterium leprae, to bovine serum albumin (BSA) by reductive amination produced the antigen epsilon-N-1-[1-deoxy-2,3-di-O-methyl-4-O-(3',6'-di-O-methyl-beta -D-glucopyranosyl)-rhamnitol]-lysyl-BSA, which proved highly sensitive in ELISA and showed good concordance with the native glycolipid in analysis of serum samples from 223 leprosy patients. Conjugates prepared from 6-O-methyl-beta-D-glucopyranosyl- or beta-D-glucopyranosyl-containing disaccharides were inactive and those containing noncyclic 3,6-di-O-methyl-glucitol showed little activity. Thus 3,6-di-O-methyl-beta-D-glucopyranose in its cyclic hemiacetal form is necessary for binding anti-glycolipid IgM from leprosy patients. Analysis of serum samples from healthy subjects showed a false-positive rate of 2.4% (four of 169) against the glycolipid and 3.6% (six of 169) against the glycoconjugate. Comparable figures for samples of sera of tuberculosis patients were 3.0% (two of 66) and 9.0% (six of 66), respectively. Alternative synthesizing strategies may diminish this cross-reactivity. The prospects of a fully synthetic specific antigen for the worldwide serodiagnosis of leprosy look promising.
    [Abstract] [Full Text] [Related] [New Search]